TiGenix N.V.

The company focuses on the development of novel treatments for musculoskeletal tissues (osteoarthritis)

TiGenix N.V. is a biomedical company, founded in February 2000 as a spin-off company of the Universities of Leuven and Ghent (Belgium). The company closely collaborates with different departments at the Universities of Leuven and Ghent, leading hospitals and pharmaceutical companies. The company has raised 13 million euros in equity and 2 million euros in grants.

TiGenix cooperates with ProStrakan, a pharmaceutical company with focus on bone diseases, on osteoarthritis research.

Frank P. Luyten, Prof., Scientific Founder & Medical Advisor
Gil Beyen, Co-Founder & CEO
Frank Hazevoets, CFO
Koen Huygens - Director Operations

Koenraad Debackere, PhD, Chairman
Frank Luyten, MD, PhD
Gil Beyen
Sven Andréasson
Marie-Hélène Plais, MD
Claude Stoufs
Raf Moons
Alain Parthoens
Willy Duron

Frank Luyten, MD, PhD
August Verbruggen, MD, PhD
Stefan Lohmander, MD, PhD
Hari Reddi, PhD
Richard Coutts, MD, PhD
Daniel Grande, PhD

Technologielaan 3
3001 Leuven
Belgium
Phone: +32-16-39-60-60
Fax: +32-16-39-60-70

The primary target of the company is osteoarthritis, one of the leading causes of disability at older age by understanding and regulating the key signalling pathways that govern the recruitment, proliferation and differentiation of musculoskeletal cells. TiGenix’ proprietary technology platform is based on research findings of the Laboratory for Skeletal Development and Joint Disorders of the Department of Rheumatology at the University of Leuven, relateding to the consistent generation of in vivo quality-controlled stable hyaline cartilage using autologous chondrocytes and precursor cell populations.

TiGenix’ lead product for cartilage repair, ChondroCelect™, has been approved as IND in the United States by the FDA.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.